Healthcare platform Docplanner has become a major player in the European healthtech market in the decade since it was founded. The company offers a suite of administrative tools for over 22M patients and around 2M doctors worldwide, including workflow digitisation and appointment booking services. The company currently operate in 13 countries, hit Unicorn status in 2021, and has been riding a recent wave of digital transformation and workforce overburdening in the healthcare sector which has spurred on demand for precisely the kind of services they provide. So it’s safe to say business is going well.
What is most compelling about Docplanner’s business journey has been its long-brewing competition with their direct competitor, the fellow Unicorn and better-funded Doctolib. The tête-à-tête with this French/German rival has seen both parties making aggressive European expansion with national acquisitions - Doctolib in Italy, France, and Germany; Docplanner in Turkey, Poland, Spain, and Latin America. With Docplanner’s 2021 acquisition of German parallel platform Jameda, however, they are making moves on Doctolib’s home turf. The company has also acquired MyDr, a leading Polish tech solutions provider.
These broad consolidation moves represent a maturation of the healthtech market which will serve both competitors well. Docplanner is certainly a key and aggressive contender in this race - and this company isn't going anywhere any time soon.
Freddie
Company Specialist at Welcome to the Jungle
